IL1B and neoplasm: CD103+ DCs from tumor-draining lymph nodes express increased levels of PD-L1, and blockade of PD-L1 and PD-1 mitigates DC dysfunction in terms of TNF-α, IL-12, and IL-1β production and enhances T-cell-stimulatory capacity [10].